Abstract:Copyright © 2021 Massachusetts Medical Society. Pulmonary hypertension is a syndrome characterized by marked remodeling of the pulmonary vasculature and a progressive rise in the pulmonary vascular load, leading to hypertrophy and remodeling of the right ventricle. Death results from right ventricular failure if pulmonary hypertension is left untreated. Pulmonary hypertension is currently defined hemodynamically by a mean pulmonary arterial pressure of higher than 20 mm Hg at rest, as measured by right heart catheterization.1 Precapillary pulmonary hypertension due to pulmonary vascular disease is further defined by an elevation in pulmonary vascular resistance of at least 3 Wood units (WU), in contrast to isolated postcapillary pulmonary hypertension, in which the pulmonary vascular resistance is less than 3 WU and the elevation in the mean pulmonary arterial pressure is due to elevated filling pressures on the left side of the heart. The several forms of pulmonary hypertension are categorized into five clinical groups (Fig. 1). This review focuses on the relatively rare form of pulmonary arterial hypertension (group 1). Immense progress has been achieved in gaining an understanding of the mechanisms, natural history, and genetic features of pulmonary arterial hypertension and in establishing targeted therapy. A full appreciation of the pathophysiology of the syndrome is important, since the diagnosis requires a thorough clinical investigation to rule out other, more common forms of pulmonary hypertension, for which treatment of the underlying disease should be the primary goal. The first anatomical description of pulmonary hypertension is credited to von Romberg.2 However, it is the advent of human right heart catheterization, first performed by Forssmann on himself in 1929,3 that led to a flurry of physiological observations on the heart and pulmonary circulation by Cournand and Richards in the 1940s. The three investigators received the Nobel Prize in Physiology or Medicine in 1956 for their seminal work. In his illuminating Nobel Lecture, Richards noted that, as a result of their collective work, ì many forms and degrees of failure were defined, and their responses to treatment measured.î 4 In 1951, Dresdale, a disciple of Cournand and Richards, and colleagues presented the first case series of patients with pulmonary hypertension of unknown cause, defined as ì primary pulmonary hypertension.î 5 Greater awareness of the disease developed in the 1960s, after an epidemic of primary pulmonary hypertension that was associated with the use of the appetite suppressant aminorex.6 This prompted the World Health Organization to convene a first meeting of pulmonary hypertension experts in 1973, to standardize the clinical and pathological nomenclature of primary pulmonary hypertension, the first attempt at an organized classification.7 The first and second meetings about pulmonary hypertension were separated by 25 years, but thereafter the World Symposium on Pulmonary Hypertension (WSPH) was convened every 5 years. The meetings brought further refinement to the classification of pulmonary hypertension, with five distinct groups Darren B. Taichman, M.D., Ph.D., Editor

An overview of the 6th World Symposium on Pulmonary Hypertension

Pathology and pathobiology of pulmonary hypertension: current insights and future directions

Exploring the patient perspective in pulmonary hypertension

Pharmacological Update and Emerging Treatments of Pulmonary Hypertension

Management of pulmonary hypertension in special conditions

Evidence and Unresolved Questions in Pulmonary Hypertension: Insights from the 5 th French Pulmonary Hypertension Network Meeting

Haemodynamic definitions and updated clinical classification of pulmonary hypertension

Diagnosis and Management of Pulmonary Hypertension: New Insights

Embracing the challenges of neonatal and paediatric pulmonary hypertension

Pulmonary Hypertension: A Contemporary Review

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management

Pulmonary Arterial Hypertension.

Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function

Genetics and precision genomics approaches to pulmonary hypertension

Publishing Trends in World Journal of Pediatric Surgery

Towards a Better Prognosis in Patients with Systemic Sclerosis-Related Pulmonary Arterial Hypertension: Recent Developments and Perspectives

Pulmonary hypertension associated with left heart disease

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021